Digoxin — MOA & Clinical Use

Digoxin is one of the oldest cardiac drugs still in use — and its dual value is what makes it unique: it strengthens a weak pump AND slows a dangerous rhythm so the heart can fill properly.

Digoxin works through two distinct mechanisms that serve two different clinical goals. First, it inhibits the sodium-potassium ATPase pump on myocardial cells, leading to increased intracellular calcium and stronger contractile force (positive inotrope). This makes it useful in systolic heart failure with reduced ejection fraction (HFrEF), where the heart needs mechanical help. Second, it slows conduction through the AV node via vagal stimulation (negative chronotrope and negative dromotrope), making it a rate-control agent for atrial fibrillation. On the NCLEX, the rate-control indication appears more frequently than the heart failure indication. Digoxin does NOT convert atrial fibrillation to normal sinus rhythm — it only controls ventricular response rate. The therapeutic range is narrow: 0.5–2.0 ng/mL, with heart failure targets often kept at the lower end (0.5–0.9 ng/mL) to reduce toxicity risk. Onset is 1–2 hours oral, 5–30 minutes IV. The long half-life (36–48 hours) means loading doses are used when rapid digitalization is needed.

Key Distinctions

Don't confuse rate control (what digoxin does) with rhythm conversion (what cardioversion or antiarrhythmics do) — digoxin slows the ventricular rate in afib but does not restore sinus rhythm. Students mix up positive inotrope (stronger contraction) with positive chronotrope (faster rate) — digoxin is a positive inotrope but a negative chronotrope. It speeds contraction force while slowing heart rate.

Clinical Pearl

Digoxin makes the heart squeeze harder but beat slower — think 'strong and slow.' Positive inotrope, negative chronotrope, same drug.